<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115648</url>
  </required_header>
  <id_info>
    <org_study_id>PEPI-Malawi</org_study_id>
    <nct_id>NCT00115648</nct_id>
  </id_info>
  <brief_title>Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission</brief_title>
  <official_title>Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if extended antiretroviral regimens given to the
      infant during the first 14 weeks of age would decrease breast milk transmission of HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a three-arm randomized, open label, clinical trial to evaluate the effectiveness of
      two extended regimens of antiretrovirals compared to infant single dose nevirapine plus AZT
      given twice daily for 1 week (comparison regimen). All infants receive the comparison regimen
      at birth and then randomized at birth to start either one of the two extended regimens after
      the first week. The extended regimens are nevirapine daily and nevirapine plus AZT daily -
      both regimens are given up to age 14 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A. Rate of HIV infection at 9 months and assess HIV infection rates at 6-8 &amp; 14 weeks, and 6, 12, 18, and 24 months. B.Determine HIV survival rates at ages 6, 12, 18, and 24 months. C. Evaluate safety of oral NVP and ZDV for 14 weeks.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine overall infant survival rates at 6, 12, 18 and 24 months.</measure>
    <time_frame>6,12,18 &amp; 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3300</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose NVP + ZDV daily for the first week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A plus NVP + ZDV daily to age 14 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A plus oral NVP daily to age 14 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>Oral NVP daily dosage</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZT</intervention_name>
    <description>Oral AZT daily</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Zidovuidne (ZDV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP and AZT</intervention_name>
    <description>Oral single dose NVP plus oral daily AZT during the first weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Nevirapine and zidovudine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP</intervention_name>
    <description>Oral NVP daily to age 14 weeks</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Nevirapine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP+AZT</intervention_name>
    <description>Oral NVP daily plus oral AZT daly to age 14 weeks</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Nevirapine plus zidovudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Had given birth within the last 24 hours

          -  Ability and willingness to give informed consent for HIV testing and enrollment into
             the study

          -  Willing to receive HIV results

          -  HIV infected

          -  Planning to deliver or had given birth at the study clinics

          -  Willing to come back for follow-up visits for 2 years postnatally

          -  Resident of Blantyre city or its suburbs

        Exclusion Criteria:

          -  HIV negative

          -  Women with discordant HIV results

          -  Women who indicate that they will not breastfeed at time of delivery

          -  Inability or unwillingness to follow any of the inclusion requirements

          -  Newborn with life-threatening condition

          -  Women who previously enrolled in this study and have a second pregnancy cannot
             reenroll
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taha E Taha, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>College of Medicine</name>
      <address>
        <city>Blantyre</city>
        <zip>1331</zip>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2005</study_first_submitted>
  <study_first_submitted_qc>June 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2005</study_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <name_title>Michael Thigpen, Medical Officer</name_title>
    <organization>Centers for Disease Control and Prevention</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>MTCT</keyword>
  <keyword>Infants</keyword>
  <keyword>africa</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

